anti-ADAM-10 CAR T-cell therapy (Carina Biotech)

N/A

Report date: 2025/01/26 19:13:36

Base Information

Drug Nameanti-ADAM-10 CAR T-cell therapy (Carina Biotech)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyBiologics > Protein drugs > Recombinant protein > Fusion protein

Mechanisms of ActionDisintegrin and metalloproteinase domain-containing protein 10 modulators

TargetsDisintegrin and metalloproteinase domain-containing protein 10

Therapy Area/IndicationsColorectal NeoplasmsBreast Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryAustralia and New Zealand

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesCarina Biotech Pty Ltd

China Registration ClassN/A

Develop Information

Active CompaniesCarina Biotech Pty Ltd

Inactive CompaniesN/A

Active IndicationsColorectal NeoplasmsBreast Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A